{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:06:11Z","timestamp":1781625971098,"version":"3.54.5"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"crossref","award":["Kidney Foundation of Canada (Grant #973281"],"award-info":[{"award-number":["Kidney Foundation of Canada (Grant #973281"]}],"id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"crossref","award":["#856581)"],"award-info":[{"award-number":["#856581)"]}],"id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40262-026-01646-0","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:54:25Z","timestamp":1777618465000},"page":"897-914","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impacts of Uremic Toxins on the Population Pharmacokinetics of Total Mycophenolic Acid and its Glucuronide Metabolite in Adult Kidney Transplant Recipients"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1938-0801","authenticated-orcid":false,"given":"Ala\u2019a R.","family":"Al-Dajani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5252-6958","authenticated-orcid":false,"given":"Yan","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0251-6375","authenticated-orcid":false,"given":"Jinal","family":"Adhiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5228-0030","authenticated-orcid":false,"given":"Puja","family":"Dhungana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6350-5258","authenticated-orcid":false,"given":"Patrick","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7362-4760","authenticated-orcid":false,"given":"Penny","family":"Colbourne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6442-895X","authenticated-orcid":false,"given":"Sita","family":"Gourishankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4548-9746","authenticated-orcid":false,"given":"Tony K. L.","family":"Kiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"1646_CR1","unstructured":"Kiang TK, MH E. Anti-rejection drugs. In: Murphy JE, editor. Clinical pharmacokinetics, 6th edn. American Society of Health-System Pharmacists; 2017."},{"key":"1646_CR2","unstructured":"Kiang, TK, MH E. Immunosuppressants. In: Beringer PE, editor. Basic clinical pharmacokinetics, 6th edn. Wolters Kluwer; 2017."},{"issue":"2","key":"1646_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","volume":"43","author":"S Bergan","year":"2021","unstructured":"Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, et al. Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2021;43(2):150\u2013200. https:\/\/doi.org\/10.1097\/FTD.0000000000000871.","journal-title":"Ther Drug Monit"},{"issue":"12","key":"1646_CR4","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1080\/17425255.2021.2027906","volume":"17","author":"Y Rong","year":"2021","unstructured":"Rong Y, Patel V, Kiang TKL. Recent lessons learned from population pharmacokinetic studies of mycophenolic acid: physiological, genomic, and drug interactions leading to the prediction of drug effects. Expert Opin Drug Metab Toxicol. 2021;17(12):1369\u2013406. https:\/\/doi.org\/10.1080\/17425255.2021.2027906.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"1646_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","volume":"46","author":"CE Staatz","year":"2007","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13\u201358. https:\/\/doi.org\/10.2165\/00003088-200746010-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1646_CR6","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00204-014-1247-1","volume":"88","author":"CE Staatz","year":"2014","unstructured":"Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol. 2014;88(7):1351\u201389. https:\/\/doi.org\/10.1007\/s00204-014-1247-1.","journal-title":"Arch Toxicol"},{"issue":"1","key":"1646_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1124\/dmd.104.001651","volume":"33","author":"N Picard","year":"2005","unstructured":"Picard N, Ratanasavanh D, Pr\u00e9maud A, Le Meur Y, Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005;33(1):139\u201346. https:\/\/doi.org\/10.1124\/dmd.104.001651.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1646_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11536640-000000000-00000","volume":"50","author":"CM Sherwin","year":"2011","unstructured":"Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011;50(1):1\u201324. https:\/\/doi.org\/10.2165\/11536640-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1646_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","volume":"34","author":"RE Bullingham","year":"1998","unstructured":"Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34(6):429\u201355. https:\/\/doi.org\/10.2165\/00003088-199834060-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1646_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/fpc.0000000000000010","volume":"24","author":"V Lamba","year":"2014","unstructured":"Lamba V, Sangkuhl K, Sanghavi K, Fish A, Altman RB, Klein TE. PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014;24(1):73\u20139. https:\/\/doi.org\/10.1097\/fpc.0000000000000010.","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"1646_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40262-017-0593-6","volume":"57","author":"TKL Kiang","year":"2018","unstructured":"Kiang TKL, Ensom MHH. Population pharmacokinetics of mycophenolic acid: an update. Clin Pharmacokinet. 2018;57(5):547\u201358. https:\/\/doi.org\/10.1007\/s40262-017-0593-6.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1646_CR12","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1111\/bcp.14590","volume":"87","author":"Y Rong","year":"2021","unstructured":"Rong Y, Jun H, Kiang TKL. Population pharmacokinetics of mycophenolic acid in paediatric patients. Br J Clin Pharmacol. 2021;87(4):1730\u201357. https:\/\/doi.org\/10.1111\/bcp.14590.","journal-title":"Br J Clin Pharmacol"},{"key":"1646_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002762","author":"DK Metz","year":"2019","unstructured":"Metz DK, Holford N, Kausman JY, Walker A, Cranswick N, Staatz CE, et al. Optimizing mycophenolic acid exposure in kidney transplant recipients: time for target concentration intervention. Transplantation. 2019. https:\/\/doi.org\/10.1097\/TP.0000000000002762.","journal-title":"Transplantation"},{"issue":"4","key":"1646_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.clinthera.2008.04.014","volume":"30","author":"DR Kuypers","year":"2008","unstructured":"Kuypers DR, de Jonge H, Naesens M, de Loor H, Halewijck E, Dekens M, et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther. 2008;30(4):673\u201383. https:\/\/doi.org\/10.1016\/j.clinthera.2008.04.014.","journal-title":"Clin Ther"},{"issue":"12","key":"1646_CR15","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s40262-019-00802-z","volume":"58","author":"TKL Kiang","year":"2019","unstructured":"Kiang TKL, Ensom MHH. Exposure-toxicity relationships of mycophenolic acid in adult kidney transplant patients. Clin Pharmacokinet. 2019;58(12):1533\u201352. https:\/\/doi.org\/10.1007\/s40262-019-00802-z.","journal-title":"Clin Pharmacokinet"},{"key":"1646_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/toxins9020052","author":"T Gryp","year":"2017","unstructured":"Gryp T, Vanholder R, Vaneechoutte M, Glorieux G. p-Cresyl sulfate. Toxins (Basel). 2017. https:\/\/doi.org\/10.3390\/toxins9020052.","journal-title":"Toxins (Basel)"},{"key":"1646_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/toxins8120358","author":"SC Leong","year":"2016","unstructured":"Leong SC, Sirich TL. Indoxyl sulfate-review of toxicity and therapeutic strategies. Toxins (Basel). 2016. https:\/\/doi.org\/10.3390\/toxins8120358.","journal-title":"Toxins (Basel)"},{"key":"1646_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/toxins10010033","author":"R Vanholder","year":"2018","unstructured":"Vanholder R, Pletinck A, Schepers E, Glorieux G. Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update. Toxins (Basel). 2018. https:\/\/doi.org\/10.3390\/toxins10010033.","journal-title":"Toxins (Basel)"},{"issue":"6","key":"1646_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16060743","volume":"16","author":"AR Al-Dajani","year":"2024","unstructured":"Al-Dajani AR, Hou QK, Kiang TKL. Liquid chromatography\u2013mass spectrometry analytical methods for the quantitation of p-cresol sulfate and indoxyl sulfate in human matrices: biological applications and diagnostic potentials. Pharmaceutics. 2024;16(6):743. https:\/\/doi.org\/10.3390\/pharmaceutics16060743.","journal-title":"Pharmaceutics"},{"issue":"6","key":"1646_CR20","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00216-012-6636-9","volume":"405","author":"J Boelaert","year":"2013","unstructured":"Boelaert J, Lynen F, Glorieux G, Eloot S, Van Landschoot M, Waterloos MA, et al. A novel UPLC\u2013MS\u2013MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients. Anal Bioanal Chem. 2013;405(6):1937\u201347. https:\/\/doi.org\/10.1007\/s00216-012-6636-9.","journal-title":"Anal Bioanal Chem"},{"issue":"2","key":"1646_CR21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jfda.2018.10.008","volume":"27","author":"CN Lin","year":"2019","unstructured":"Lin CN, Wu IW, Huang YF, Peng SY, Huang YC, Ning HC. Measuring serum total and free indoxyl sulfate and p-cresyl sulfate in chronic kidney disease using UPLC\u2013MS\/MS. J Food Drug Anal. 2019;27(2):502\u20139. https:\/\/doi.org\/10.1016\/j.jfda.2018.10.008.","journal-title":"J Food Drug Anal"},{"issue":"6","key":"1646_CR22","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/ndt\/gfab004","volume":"36","author":"G Glorieux","year":"2021","unstructured":"Glorieux G, Vanholder R, Van Biesen W, Pletinck A, Schepers E, Neirynck N, et al. Free p-cresyl sulfate shows the highest association with cardiovascular outcome in chronic kidney disease. Nephrol Dial Transplant. 2021;36(6):998\u20131005. https:\/\/doi.org\/10.1093\/ndt\/gfab004.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1646_CR23","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/ndt\/gfr453","volume":"27","author":"IW Wu","year":"2012","unstructured":"Wu IW, Hsu KH, Hsu HJ, Lee CC, Sun CY, Tsai CJ, et al. Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients\u2014a prospective cohort study. Nephrol Dial Transplant. 2012;27(3):1169\u201375. https:\/\/doi.org\/10.1093\/ndt\/gfr453.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1646_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.70065","volume":"137","author":"R Renaldi","year":"2025","unstructured":"Renaldi R, Wiguna T, Persico AM, Tanra AJ. p-Cresol and p-cresyl sulphate boost oxidative stress: a systematic review of recent evidence. Basic Clin Pharmacol Toxicol. 2025;137(1):e70065. https:\/\/doi.org\/10.1111\/bcpt.70065.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"1646_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/ndt\/gft367","volume":"29","author":"J Poveda","year":"2014","unstructured":"Poveda J, Sanchez-Ni\u00f1o MD, Glorieux G, Sanz AB, Egido J, Vanholder R, et al. p-Cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. Nephrol Dial Transplant. 2014;29(1):56\u201364. https:\/\/doi.org\/10.1093\/ndt\/gft367.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"1646_CR26","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00228-014-1709-7","volume":"70","author":"KJ Barnes","year":"2014","unstructured":"Barnes KJ, Rowland A, Polasek TM, Miners JO. Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins. Eur J Clin Pharmacol. 2014;70(9):1097\u2013106. https:\/\/doi.org\/10.1007\/s00228-014-1709-7.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"1646_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4549","volume":"33","author":"Y Rong","year":"2019","unstructured":"Rong Y, Kiang TKL. Development and validation of a sensitive liquid-chromatography tandem mass spectrometry assay for mycophenolic acid and metabolites in HepaRG cell culture: characterization of metabolism interactions between p-cresol and mycophenolic acid. Biomed Chromatogr. 2019;33(8):e4549. https:\/\/doi.org\/10.1002\/bmc.4549.","journal-title":"Biomed Chromatogr"},{"issue":"2","key":"1646_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/toxsci\/kfz231","volume":"173","author":"Y Rong","year":"2020","unstructured":"Rong Y, Kiang TKL. Mechanisms of metabolism interaction between p-cresol and mycophenolic acid. Toxicol Sci. 2020;173(2):267\u201379. https:\/\/doi.org\/10.1093\/toxsci\/kfz231.","journal-title":"Toxicol Sci"},{"issue":"10","key":"1646_CR29","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1093\/ndt\/gfw009","volume":"31","author":"R Poesen","year":"2016","unstructured":"Poesen R, Evenepoel P, de Loor H, Bammens B, Claes K, Sprangers B, et al. The influence of renal transplantation on retained microbial-human co-metabolites. Nephrol Dial Transplant. 2016;31(10):1721\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfw009.","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"1646_CR30","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.34067\/kid.0000272020","volume":"1","author":"E Te Linde","year":"2020","unstructured":"Te Linde E, van Roij CJM, Meijers BKI, De Loor H, Kessels RPC, Wetzels JFM. Cognitive function and uremic toxins after kidney transplantation: an exploratory study. Kidney360. 2020;1(12):1398\u2013406. https:\/\/doi.org\/10.34067\/kid.0000272020.","journal-title":"Kidney360"},{"key":"1646_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14010015","author":"C Andr\u00e9","year":"2021","unstructured":"Andr\u00e9 C, Mernissi T, Choukroun G, Bennis Y, Kamel S, Liabeuf S, et al. The prescription of drugs that inhibit organic anion transporters 1 or 3 is associated with the plasma accumulation of uremic toxins in kidney transplant recipients. Toxins (Basel). 2021. https:\/\/doi.org\/10.3390\/toxins14010015.","journal-title":"Toxins (Basel)"},{"issue":"3","key":"1646_CR32","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.transproceed.2011.11.023","volume":"44","author":"ST Huang","year":"2012","unstructured":"Huang ST, Shu KH, Cheng CH, Wu MJ, Yu TM, Chuang YW, et al. Serum total p-cresol and indoxyl sulfate correlated with stage of chronic kidney disease in renal transplant recipients. Transplant Proc. 2012;44(3):621\u20134. https:\/\/doi.org\/10.1016\/j.transproceed.2011.11.023.","journal-title":"Transplant Proc"},{"issue":"7","key":"1646_CR33","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.transproceed.2015.02.033","volume":"47","author":"G Ligabue","year":"2015","unstructured":"Ligabue G, Damiano F, Cuoghi A, De Biasi S, Bellei E, Granito M, et al. p-Cresol and cardiovascular risk in kidney transplant recipients. Transplant Proc. 2015;47(7):2121\u20135. https:\/\/doi.org\/10.1016\/j.transproceed.2015.02.033.","journal-title":"Transplant Proc"},{"issue":"3","key":"1646_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40261-022-01121-1","volume":"42","author":"Y Rong","year":"2022","unstructured":"Rong Y, Colbourne P, Gourishankar S, Kiang TKL. Significant correlations between p-cresol sulfate and mycophenolic acid plasma concentrations in adult kidney transplant recipients. Clin Drug Investig. 2022;42(3):207\u201319. https:\/\/doi.org\/10.1007\/s40261-022-01121-1.","journal-title":"Clin Drug Investig"},{"issue":"7","key":"1646_CR35","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1016\/j.tiv.2015.07.020","volume":"29","author":"HA Mutsaers","year":"2015","unstructured":"Mutsaers HA, Caetano-Pinto P, Seegers AE, Dankers AC, van den Broek PH, Wetzels JF, et al. Proximal tubular efflux transporters involved in renal excretion of p-cresyl sulfate and p-cresyl glucuronide: implications for chronic kidney disease pathophysiology. Toxicol In Vitro. 2015;29(7):1868\u201377. https:\/\/doi.org\/10.1016\/j.tiv.2015.07.020.","journal-title":"Toxicol In Vitro"},{"issue":"1","key":"1646_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/00498254.2020.1813352","volume":"51","author":"J Berthier","year":"2021","unstructured":"Berthier J, Benmameri M, Sauvage FL, Fabre G, Chantemargue B, Arnion H, et al. MRP4 is responsible for the efflux transport of mycophenolic acid \u03b2-d glucuronide (MPAG) from hepatocytes to blood. Xenobiotica. 2021;51(1):105\u201314. https:\/\/doi.org\/10.1080\/00498254.2020.1813352.","journal-title":"Xenobiotica"},{"issue":"8","key":"1646_CR37","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1093\/ndt\/gfq785","volume":"26","author":"Y Miyamoto","year":"2011","unstructured":"Miyamoto Y, Watanabe H, Noguchi T, Kotani S, Nakajima M, Kadowaki D, et al. Organic anion transporters play an important role in the uptake of p-cresyl sulfate, a uremic toxin, in the kidney. Nephrol Dial Transplant. 2011;26(8):2498\u2013502. https:\/\/doi.org\/10.1093\/ndt\/gfq785.","journal-title":"Nephrol Dial Transplant"},{"key":"1646_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136328","author":"P Spicher","year":"2025","unstructured":"Spicher P, Brazier F, Laville SM, Liabeuf S, Kamel S, Culot M, et al. Transporter-mediated interactions between uremic toxins and drugs: a hidden driver of toxicity in chronic kidney disease. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26136328.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1646_CR39","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.bcp.2007.03.024","volume":"74","author":"Y Uwai","year":"2007","unstructured":"Uwai Y, Motohashi H, Tsuji Y, Ueo H, Katsura T, Inui K. Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3. Biochem Pharmacol. 2007;74(1):161\u20138. https:\/\/doi.org\/10.1016\/j.bcp.2007.03.024.","journal-title":"Biochem Pharmacol"},{"key":"1646_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.116.005022","author":"SC Hung","year":"2017","unstructured":"Hung SC, Kuo KL, Wu CC, Tarng DC. Indoxyl sulfate: a novel cardiovascular risk factor in chronic kidney disease. J Am Heart Assoc. 2017. https:\/\/doi.org\/10.1161\/jaha.116.005022.","journal-title":"J Am Heart Assoc"},{"issue":"1-2","key":"1646_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/s0014-2999(03)01530-9","volume":"466","author":"A Enomoto","year":"2003","unstructured":"Enomoto A, Takeda M, Taki K, Takayama F, Noshiro R, Niwa T, et al. Interactions of human organic anion as well as cation transporters with indoxyl sulfate. Eur J Pharmacol. 2003;466(1\u20132):13\u201320. https:\/\/doi.org\/10.1016\/s0014-2999(03)01530-9.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"1646_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018438","volume":"6","author":"HA Mutsaers","year":"2011","unstructured":"Mutsaers HA, van den Heuvel LP, Ringens LH, Dankers AC, Russel FG, Wetzels JF, et al. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PLoS ONE. 2011;6(4):e18438. https:\/\/doi.org\/10.1371\/journal.pone.0018438.","journal-title":"PLoS ONE"},{"issue":"5","key":"1646_CR43","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1046\/j.1523-1755.2002.00318.x","volume":"61","author":"T Deguchi","year":"2002","unstructured":"Deguchi T, Ohtsuki S, Otagiri M, Takanaga H, Asaba H, Mori S, et al. Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. Kidney Int. 2002;61(5):1760\u20138. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00318.x.","journal-title":"Kidney Int"},{"issue":"12","key":"1646_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70097","volume":"17","author":"Y Suzuki","year":"2024","unstructured":"Suzuki Y, Matsunaga N, Aoyama T, Ogami C, Hasegawa C, Iida S, et al. Population pharmacokinetic analysis identifies an absorption process model for mycophenolic acid in patients with renal transplant. Clin Transl Sci. 2024;17(12):e70097. https:\/\/doi.org\/10.1111\/cts.70097.","journal-title":"Clin Transl Sci"},{"issue":"10-11","key":"1646_CR45","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/00498254.2023.2287168","volume":"53","author":"K Rexiti","year":"2023","unstructured":"Rexiti K, Jiang X, Kong Y, Chen X, Liu H, Peng H, et al. Population pharmacokinetics of mycophenolic acid and dose optimisation in adult Chinese kidney transplant recipients. Xenobiotica. 2023;53(10\u201311):603\u201312. https:\/\/doi.org\/10.1080\/00498254.2023.2287168.","journal-title":"Xenobiotica"},{"issue":"8","key":"1646_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.70275","volume":"39","author":"K Deng","year":"2025","unstructured":"Deng K, Liu J, Liu Y, Huang J, Xi Q, Yang G. Population pharmacokinetics and limited sampling strategy of mycophenolate mofetil for patients in early period after kidney transplantation. Clin Transplant. 2025;39(8):e70275. https:\/\/doi.org\/10.1111\/ctr.70275.","journal-title":"Clin Transplant"},{"key":"1646_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.859351","volume":"13","author":"P Wang","year":"2022","unstructured":"Wang P, Xie H, Zhang Q, Tian X, Feng Y, Qin Z, et al. Population pharmacokinetics of mycophenolic acid in renal transplant patients: a comparison of the early and stable posttransplant stages. Front Pharmacol. 2022;13:859351. https:\/\/doi.org\/10.3389\/fphar.2022.859351.","journal-title":"Front Pharmacol"},{"key":"1646_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/medsci13040235","author":"A Tsyplakova","year":"2025","unstructured":"Tsyplakova A, Catic-Djor\u0111evic A, Stefanovi\u0107 N, Karalis VD. Optimizing mycophenolate therapy in renal transplant patients using machine learning and population pharmacokinetic modeling. Med Sci Basel. 2025. https:\/\/doi.org\/10.3390\/medsci13040235.","journal-title":"Med Sci Basel"},{"issue":"1","key":"1646_CR49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/17425255.2024.2409257","volume":"21","author":"AR Al-Dajani","year":"2025","unstructured":"Al-Dajani AR, Kiang TKL. A high-throughput liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of p-cresol sulfate, p-cresol glucuronide, indoxyl sulfate, and indoxyl glucuronide in HepaRG culture medium and the demonstration of mefenamic acid as a potent and selective detoxifying agent. Expert Opin Drug Metab Toxicol. 2025;21(1):81\u201393. https:\/\/doi.org\/10.1080\/17425255.2024.2409257.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1646_CR50","unstructured":"U.S. Food and Drug Administration. M10 bioanalytical method validation and study sample analysis. 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m10-bioanalytical-method-validation-and-study-sample-analysis. Accessed 10 Dec 2025."},{"key":"1646_CR51","unstructured":"Lixoft: Monolix Suite 2024R1 - Monolix. https:\/\/monolixsuite.slp-software.com\/monolix\/2024R1\/. Accessed 10 Dec 2025."},{"issue":"9","key":"1646_CR52","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s40262-023-01280-0","volume":"62","author":"Y Rong","year":"2023","unstructured":"Rong Y, Wichart J, Hamiwka L, Kiang TKL. Significant effects of renal function on mycophenolic acid total clearance in pediatric kidney transplant recipients with population pharmacokinetic modeling. Clin Pharmacokinet. 2023;62(9):1289\u2013303. https:\/\/doi.org\/10.1007\/s40262-023-01280-0.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1646_CR53","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s13318-018-0525-3","volume":"44","author":"Y Rong","year":"2019","unstructured":"Rong Y, Mayo P, Ensom MHH, Kiang TKL. Population pharmacokinetic analysis of immediate-release oral tacrolimus co-administered with mycophenolate mofetil in corticosteroid-free adult kidney transplant recipients. Eur J Drug Metab Pharmacokinet. 2019;44(3):409\u201322. https:\/\/doi.org\/10.1007\/s13318-018-0525-3.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"1646_CR54","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40268-020-00323-2","volume":"20","author":"H Jun","year":"2020","unstructured":"Jun H, Rong Y, Yih C, Ho J, Cheng W, Kiang TKL. Comparisons of four protein-binding models characterizing the pharmacokinetics of unbound phenytoin in adult patients using non-linear mixed-effects modeling. Drugs R D. 2020;20(4):343\u201358. https:\/\/doi.org\/10.1007\/s40268-020-00323-2.","journal-title":"Drugs R D"},{"issue":"11","key":"1646_CR55","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s40262-019-00771-3","volume":"58","author":"Y Rong","year":"2019","unstructured":"Rong Y, Mayo P, Ensom MHH, Kiang TKL. Population pharmacokinetics of mycophenolic acid co-administered with tacrolimus in corticosteroid-free adult kidney transplant patients. Clin Pharmacokinet. 2019;58(11):1483\u201395. https:\/\/doi.org\/10.1007\/s40262-019-00771-3.","journal-title":"Clin Pharmacokinet"},{"key":"1646_CR56","unstructured":"PubChem: Mycophenolic acid. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/446541. Accessed 10 Dec 2025."},{"key":"1646_CR57","unstructured":"PubChem: Mycophenolic acid glucuronide. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/6442661. Accessed 10 Dec 2025."},{"key":"1646_CR58","unstructured":"PubChem: p-Cresol sulfate. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/4615423. Accessed 10 Dec 2025."},{"key":"1646_CR59","unstructured":"PubChem: Indoxyl sulfate. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Indoxyl-sulfate. Accessed 10 Dec 2025."},{"key":"1646_CR60","unstructured":"PubChem: Indoxyl glucuronide. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/2733785. Accessed 10 Dec 2025."},{"key":"1646_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00340","volume":"11","author":"C Sheng","year":"2020","unstructured":"Sheng C, Zhao Q, Niu W, Qiu X, Zhang M, Jiao Z. Effect of protein binding on exposure of unbound and total mycophenolic acid: a population pharmacokinetic analysis in Chinese adult kidney transplant recipients. Front Pharmacol. 2020;11:340. https:\/\/doi.org\/10.3389\/fphar.2020.00340.","journal-title":"Front Pharmacol"},{"key":"1646_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/ph18050621","author":"YJ Lee","year":"2025","unstructured":"Lee YJ, Kang G, Zang DY, Lee DH. Development of a population pharmacokinetic model of levofloxacin in healthy adults and identification of optimal dosing regimens. Pharmaceuticals (Basel). 2025. https:\/\/doi.org\/10.3390\/ph18050621.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1646_CR63","unstructured":"Lixoft: Monolix - proposal function. https:\/\/monolixsuite.slp-software.com\/monolix\/2024R1\/proposal. Accessed 10 Dec 2025."},{"issue":"8","key":"1646_CR64","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/BF03261928","volume":"51","author":"TK Kiang","year":"2012","unstructured":"Kiang TK, Sherwin CM, Spigarelli MG, Ensom MH. Fundamentals of population pharmacokinetic modelling: modelling and software. Clin Pharmacokinet. 2012;51(8):515\u201325. https:\/\/doi.org\/10.1007\/BF03261928.","journal-title":"Clin Pharmacokinet"},{"key":"1646_CR65","doi-asserted-by":"publisher","unstructured":"Sherwin CM, Kiang TK, Spigarelli MG, Ensom MH. Fundamentals of population pharmacokinetic modelling: validation methods. Clin Pharmacokinet. 2012;51(9):573\u201390. https:\/\/doi.org\/10.2165\/11634200-000000000-00000. 10.1007\/BF03261932","DOI":"10.2165\/11634200-000000000-00000"},{"issue":"3","key":"1646_CR66","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1253\/circj.CJ-15-0949","volume":"80","author":"S Liabeuf","year":"2016","unstructured":"Liabeuf S, Desjardins L, Massy ZA, Brazier F, Westeel PF, Mazouz H, et al. Levels of indoxyl sulfate in kidney transplant patients, and the relationship with hard outcomes. Circ J. 2016;80(3):722\u201330. https:\/\/doi.org\/10.1253\/circj.CJ-15-0949.","journal-title":"Circ J"},{"issue":"3","key":"1646_CR67","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1093\/ndt\/gfq580","volume":"26","author":"IW Wu","year":"2011","unstructured":"Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant. 2011;26(3):938\u201347. https:\/\/doi.org\/10.1093\/ndt\/gfq580.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1646_CR68","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/ckj\/sfaa121","volume":"14","author":"S Yamamoto","year":"2021","unstructured":"Yamamoto S, Fuller DS, Komaba H, Nomura T, Massy ZA, Bieber B, et al. Serum total indoxyl sulfate and clinical outcomes in hemodialysis patients: results from the Japan Dialysis Outcomes and Practice Patterns Study. Clin Kidney J. 2021;14(4):1236\u201343. https:\/\/doi.org\/10.1093\/ckj\/sfaa121.","journal-title":"Clin Kidney J"},{"issue":"6-7","key":"1646_CR69","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00216-012-6277-z","volume":"404","author":"A Cuoghi","year":"2012","unstructured":"Cuoghi A, Caiazzo M, Bellei E, Monari E, Bergamini S, Palladino G, et al. Quantification of p-cresol sulphate in human plasma by selected reaction monitoring. Anal Bioanal Chem. 2012;404(6\u20137):2097\u2013104. https:\/\/doi.org\/10.1007\/s00216-012-6277-z.","journal-title":"Anal Bioanal Chem"},{"key":"1646_CR70","unstructured":"Lixoft: Monolix Suite 2024R1 - Simulx. https:\/\/monolixsuite.slp-software.com\/simulx\/2024R1\/. Accessed 10 Dec 2025."},{"issue":"1","key":"1646_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47876-0","volume":"9","author":"JH Kim","year":"2019","unstructured":"Kim JH, Han N, Kim MG, Kim YW, Jang H, Yun HY, et al. Model based development of tacrolimus dosing algorithm considering CYP3A5 genotypes and mycophenolate mofetil drug interaction in stable kidney transplant recipients. Sci Rep. 2019;9(1):11740. https:\/\/doi.org\/10.1038\/s41598-019-47876-0.","journal-title":"Sci Rep"},{"issue":"2","key":"1646_CR72","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/FTD.0b013e31819c077c","volume":"31","author":"A Hulin","year":"2009","unstructured":"Hulin A, Blanchet B, Audard V, Barau C, Furlan V, Durrbach A, et al. Comparison of 3 estimation methods of mycophenolic acid AUC based on a limited sampling strategy in renal transplant patients. Ther Drug Monit. 2009;31(2):224\u201332. https:\/\/doi.org\/10.1097\/FTD.0b013e31819c077c.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"1646_CR73","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1111\/jcpt.13488","volume":"46","author":"CL Yang","year":"2021","unstructured":"Yang CL, Sheng CC, Liao GY, Su Y, Feng LJ, Xia Q, et al. Genetic polymorphisms in metabolic enzymes and transporters have no impact on mycophenolic acid pharmacokinetics in adult kidney transplant patients co-treated with tacrolimus: a population analysis. J Clin Pharm Ther. 2021;46(6):1564\u201375. https:\/\/doi.org\/10.1111\/jcpt.13488.","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"1646_CR74","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1365-2125.2005.02398.x","volume":"60","author":"S Cremers","year":"2005","unstructured":"Cremers S, Schoemaker R, Scholten E, den Hartigh J, K\u00f6nig-Quartel J, van Kan E, et al. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol. 2005;60(3):249\u201356. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02398.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1646_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245880","volume":"16","author":"L Quintairos","year":"2021","unstructured":"Quintairos L, Colom H, Mill\u00e1n O, Fortuna V, Espinosa C, Guirado L, et al. Early prognostic performance of miR155-5p monitoring for the risk of rejection: logistic regression with a population pharmacokinetic approach in adult kidney transplant patients. PLoS ONE. 2021;16(1):e0245880. https:\/\/doi.org\/10.1371\/journal.pone.0245880.","journal-title":"PLoS ONE"},{"key":"1646_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105370","volume":"150","author":"JE Res\u00e9ndiz-Galv\u00e1n","year":"2020","unstructured":"Res\u00e9ndiz-Galv\u00e1n JE, Romano-Aguilar M, Medell\u00edn-Garibay SE, Mil\u00e1n-Segovia RDC, Ni\u00f1o-Moreno PDC, Jung-Cook H, et al. Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen. Eur J Pharm Sci. 2020;150:105370. https:\/\/doi.org\/10.1016\/j.ejps.2020.105370.","journal-title":"Eur J Pharm Sci"},{"key":"1646_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-025-01587-0","author":"P Dhungana","year":"2025","unstructured":"Dhungana P, Dam A, Kiang TKL. Clinical pharmacokinetic-pharmacodynamic relationships of pharmacological strategies for attenuating p-cresyl sulfate in patients with kidney disease. Clin Pharmacokinet. 2025. https:\/\/doi.org\/10.1007\/s40262-025-01587-0.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1646_CR78","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/FTD.0b013e31821633a6","volume":"33","author":"F Saint-Marcoux","year":"2011","unstructured":"Saint-Marcoux F, Vandierdonck S, Pr\u00e9maud A, Debord J, Rousseau A, Marquet P. Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients. Ther Drug Monit. 2011;33(3):285\u201394. https:\/\/doi.org\/10.1097\/FTD.0b013e31821633a6.","journal-title":"Ther Drug Monit"},{"issue":"11","key":"1646_CR79","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","volume":"7","author":"Y Le Meur","year":"2007","unstructured":"Le Meur Y, B\u00fcchler M, Thierry A, Caillard S, Villemain F, Lavaud S, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007;7(11):2496\u2013503. https:\/\/doi.org\/10.1111\/j.1600-6143.2007.01983.x.","journal-title":"Am J Transplant"},{"key":"1646_CR80","unstructured":"Limoges. https:\/\/pharmaco.chu-limoges.fr\/. Accessed 14 Mar 2026."},{"issue":"4","key":"1646_CR81","doi-asserted-by":"publisher","first-page":"475","DOI":"10.18433\/j3m89q","volume":"17","author":"T Sato","year":"2014","unstructured":"Sato T, Yamaguchi H, Kogawa T, Abe T, Mano N. Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver. J Pharm Pharm Sci. 2014;17(4):475\u201384. https:\/\/doi.org\/10.18433\/j3m89q.","journal-title":"J Pharm Pharm Sci"},{"key":"1646_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2021.115553","volume":"425","author":"Y Rong","year":"2021","unstructured":"Rong Y, Kiang TKL. Characterization of human sulfotransferases catalyzing the formation of p-cresol sulfate and identification of mefenamic acid as a potent metabolism inhibitor and potential therapeutic agent for detoxification. Toxicol Appl Pharmacol. 2021;425:115553. https:\/\/doi.org\/10.1016\/j.taap.2021.115553.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"7","key":"1646_CR83","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40262-017-0603-8","volume":"57","author":"H Colom","year":"2018","unstructured":"Colom H, Andreu F, van Gelder T, Hesselink DA, de Winter BCM, Bestard O, et al. Prediction of free from total mycophenolic acid concentrations in stable renal transplant patients: a population-based approach. Clin Pharmacokinet. 2018;57(7):877\u201393. https:\/\/doi.org\/10.1007\/s40262-017-0603-8.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1646_CR84","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40268-020-00319-y","volume":"20","author":"F Riglet","year":"2020","unstructured":"Riglet F, Bertrand J, Barrail-Tran A, Verstuyft C, Michelon H, Benech H, et al. Population pharmacokinetic model of plasma and cellular mycophenolic acid in kidney transplant patients from the CIMTRE study. Drugs R D. 2020;20(4):331\u201342. https:\/\/doi.org\/10.1007\/s40268-020-00319-y.","journal-title":"Drugs R D"},{"issue":"7","key":"1646_CR85","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2165\/11312600-000000000-00000","volume":"48","author":"RM van Hest","year":"2009","unstructured":"van Hest RM, van Gelder T, Vulto AG, Shaw LM, Mathot RA. Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2009;48(7):463\u201376. https:\/\/doi.org\/10.2165\/11312600-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"1646_CR86","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2165\/00003088-200544080-00005","volume":"44","author":"A Pr\u00e9maud","year":"2005","unstructured":"Pr\u00e9maud A, Debord J, Rousseau A, Le Meur Y, Toupance O, Lebranchu Y, et al. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet. 2005;44(8):837\u201347. https:\/\/doi.org\/10.2165\/00003088-200544080-00005.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1646_CR87","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/01.ftd.0000162231.90811.38","volume":"27","author":"A Pr\u00e9maud","year":"2005","unstructured":"Pr\u00e9maud A, Le Meur Y, Debord J, Szelag JC, Rousseau A, Hoizey G, et al. Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit. 2005;27(3):354\u201361. https:\/\/doi.org\/10.1097\/01.ftd.0000162231.90811.38.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"1646_CR88","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00228-023-03587-0","volume":"80","author":"K Koloskoff","year":"2024","unstructured":"Koloskoff K, Benito S, Chambon L, Dayan F, Marquet P, Jacqz-Aigrain E, et al. Limited sampling strategy and population pharmacokinetic model of mycophenolic acid in pediatric patients with systemic lupus erythematosus: application of a double gamma absorption model with SAEM algorithm. Eur J Clin Pharmacol. 2024;80(1):83\u201392. https:\/\/doi.org\/10.1007\/s00228-023-03587-0.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"1646_CR89","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.1111\/bcp.15389","volume":"88","author":"TM Nanga","year":"2022","unstructured":"Nanga TM, Woillard JB, Rousseau A, Marquet P, Pr\u00e9maud A. Population pharmacokinetics and Bayesian estimation of mycophenolate mofetil in patients with autoimmune hepatitis. Br J Clin Pharmacol. 2022;88(11):4732\u201341. https:\/\/doi.org\/10.1111\/bcp.15389.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1646_CR90","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1177\/0091270009357429","volume":"50","author":"W Zhao","year":"2010","unstructured":"Zhao W, Fakhoury M, Desch\u00eanes G, Roussey G, Brochard K, Niaudet P, et al. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J Clin Pharmacol. 2010;50(11):1280\u201391. https:\/\/doi.org\/10.1177\/0091270009357429.","journal-title":"J Clin Pharmacol"},{"key":"1646_CR91","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.phrs.2015.07.012","volume":"99","author":"JB Woillard","year":"2015","unstructured":"Woillard JB, Saint-Marcoux F, Monchaud C, Youdar\u00e8ne R, Pouche L, Marquet P. Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients. Pharmacol Res. 2015;99:308\u201315. https:\/\/doi.org\/10.1016\/j.phrs.2015.07.012.","journal-title":"Pharmacol Res"},{"issue":"3","key":"1646_CR92","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/cpt.3510","volume":"117","author":"AC Dibbets","year":"2025","unstructured":"Dibbets AC, Koldeweij C, Osinga EP, Scheepers HCJ, de Wildt SN. Barriers and facilitators for bringing model-informed precision dosing to the patient\u2019s bedside: a systematic review. Clin Pharmacol Ther. 2025;117(3):633\u201345. https:\/\/doi.org\/10.1002\/cpt.3510.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1646_CR93","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2165\/11596380-000000000-00000","volume":"50","author":"CE Staatz","year":"2011","unstructured":"Staatz CE, Tett SE. Maximum a posteriori Bayesian estimation of mycophenolic acid area under the concentration-time curve: is this clinically useful for dosage prediction yet? Clin Pharmacokinet. 2011;50(12):759\u201372. https:\/\/doi.org\/10.2165\/11596380-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"1646_CR94","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s40261-018-0694-5","volume":"38","author":"TKL Kiang","year":"2018","unstructured":"Kiang TKL, Partovi N, Shapiro RJ, Berman JM, Collier AC, Ensom MHH. Regression and genomic analyses on the association between dose-normalized mycophenolic acid exposure and absolute neutrophil count in steroid-free, de novo kidney transplant recipients. Clin Drug Investig. 2018;38(11):1011\u201322. https:\/\/doi.org\/10.1007\/s40261-018-0694-5.","journal-title":"Clin Drug Investig"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01646-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01646-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01646-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:07:11Z","timestamp":1781622431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01646-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1646"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01646-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest pertaining to the preparation of this manuscript. Dr. Tony Kiang serves on the Editorial Board of\n                      Clinical Pharmacokinetics\n                      but was not involved in the editorial process of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data can be obtained from the corresponding author upon reasonable request, subject to ethical and privacy considerations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This work was approved by the University of Alberta Research Ethics Boards (study ID Pro00113219 and Pro00121659), which adhered to the Declaration of Helsinki principles.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written consents were obtained per our ethics protocols (study ID Pro00113219 and Pro00121659).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Granted by our ethics protocols stated above.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Project conception: Tony Kiang; Patient recruitment, sample collection, data extraction: Ala\u2019A Al-Dajani, Jinal Adhiya, Puja Dhungana, Yan Rong; Sample analyses: Ala\u2019A Al-Dajani and Jinal Adhiya; Modelling and simulation: Ala\u2019A Al-Dajani, Yan Rong, Patrick Mayo, Tony Kiang; Data interpretation: Tony Kiang, Ala\u2019A Al-Dajani, Yan Rong, Penny Colbourne, Sita Gourishankar; Manuscript preparation: Ala\u2019A Al-Dajani, Yan Rong, Tony Kiang; Manuscript editing and approval for submission: all listed authors.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}